Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cellsPARIS, ...

Some high-grade prostate cancers, such as intraductal carcinoma of the prostate, are not clearly visible on PSMA PET. For patients with intraductal carcinoma of the prostate (IDC-P), prostate-specific ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...